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of the bone marrow and lowered serum tryptase level.
Objective: We aimed to determine whether midostaurin
improves health-related quality of life (QOL) and MC
mediator–related symptoms in patients with advSM.
Methods: In 116 patients with systemic mastocytosis (89
patients with advSM fulfilling the strict inclusion criteria of the
D2201 study [ClinicalTrials.gov identifier NCT00782067]), QOL
and symptom burden were assessed during treatment with
midostaurin by using the 12-Item Short-Form Health Survey
(SF-12) and the Memorial Symptom Assessment Scale patient-
reported questionnaires, respectively. MC mediator–related
symptoms were evaluated by using a specific physician-reported
questionnaire.
Results: Over the first 6 cycles of treatment with midostaurin
(ie, 6 months), patients experienced significant improvements in
total SF-12 and Memorial Symptom Assessment Scale scores, as
well as in subscores of each instrument. These improvements
were durable during 36 months of follow-up. Similarly, we
found substantial improvements (67%-100%) in all MC
mediator–related symptoms.
Conclusion: QOL and MC mediator–related symptoms
significantly improve with midostaurin treatment in patients
with advSM (ClinicalTrials.gov identifier, NCT00782067). (J
Allergy Clin Immunol 2020;146:356-66.)
Key words: Advanced systemic mastocytosis, KIT mutation, masto-
cytosis, mediator symptoms, midostaurin, quality of life, tryptase,
skin lesions of mastocytosis
Mastocytosis is characterized by symptoms due to the
proliferation and accumulation of neoplastic mast cells (MCs)
in 1 or more organs, most frequently the bone marrow (BM) and
skin.1,2 Mastocytosis categories encompass nonadvanced forms,
including cutaneous mastocytosis, indolent systemic mastocyto-
sis (SM), and smoldering SM, as well as advanced forms,
including aggressive SM (ASM), SM with an associated hemato-
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Serum levels of tryptase, an enzyme mainly produced by MCs,
correlate with total MC burden.7-9 Advanced SM (advSM) has a
poor prognosis, with limited treatment options.6-8,10
In addition to signs and symptoms related to MC infiltration in
BM and other organs, patients with advSM also experience
symptoms due to release of MC mediators.11 These mediators
include histamine, cytokines, and lipid mediators, and their
release is associated with various symptoms affecting the skin
(eg, pruritus, wheals, blisters), gastrointestinal tract (eg, abdom-
inal pain, diarrhea, nausea and vomiting), and other organs, and
it can also present as anaphylaxis, flushing, headache, and fa-
tigue.12 Furthermore, approximately half of all patients with
advSM develop specific skin lesions of mastocytosis.13 Together,
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358 HARTMANN ET ALMidostaurin is an orally active multikinase inhibitor that
targets KIT and also blocks immunoglobulin E (IgE)–dependent
secretion of mediators in vitro.14,15 Previously, we reported pri-
mary results of the D2201 study—a global, phase 2, single-arm,
open-label study of midostaurin that demonstrated a 60%
response rate using modified Valent response criteria and modi-
fied Cheson criteria to adjudicate advSM-related organ damage
and measures of MC burden, including BM MC infiltration,
serum tryptase levels, and splenomegaly.16 In the present anal-
ysis, we sought to describe inmore detail the effect of midostaurin
on QOL and MC mediator–related symptoms in patients enrolled
in the D2201 study.METHODS
Study design
The patient population, eligibility criteria, and study design have been
previously described; the baseline characteristics of the study population are
summarized in Table E1 in the Online Repository (at www.jacionline.org)16
The study (ClinicalTrials.gov identifier NCT00782067) was designed and re-
ported in accordance with the provisions of the Declaration of Helsinki and
approved by the institutional review board at each participating institution.
All patients provided written informed consent. Briefly, adult patients (aged
>_18 years) with histologically documented ASM, SM-AHN, or MC leukemia
per World Health Organization criteria17 were enrolled in this study and
received oral midostaurin, 100 mg twice daily in 28-day continuous cycles.
Eligibility and response were adjudicated by a study steering committee
(SSC).16Role of the funding source
The study was designed by Novartis Pharmaceuticals Corporation and by
the SSC members. The study was sponsored and funded by Novartis
Pharmaceuticals Corporation. Data were collected and analyzed by the
sponsor in conjunction with the authors, who had full access to the data.
The article was written by the authors with the support of ArticulateScience
LLC, which was funded by the sponsor.Patient population
QOL analyses were performed on the intention-to-treat (ITT) population to
include all available data in the statistical analyses. The ITT population
comprised all patients in the study (N 5 116), including all patients without
measurable C-findings at baseline or with C-findings at baseline that were
considered by the SSC to be probably unrelated to mastocytosis (n 5 27).16
C-findings included cytopenias and liver function abnormalities such as portal
hypertension and ascites, malabsorption, hypoalbuminemia, weight loss of at
least 10% in the prior 6months, and large osteolytic bone lesions or pathologic
fractures; the latter 2 were considered not measurable and could not be the sole
C-finding present to be evaluable. Patients were enrolled at 29 centers
worldwide from July 2009 to July 2012.16 Detailed demographics for the study
population have been previously reported and are summarized in Table E1 in
the Online Repository.16 The primary efficacy population (PEP [defined as pa-
tients with >_1 measurable C-finding considered related to SM as adjudicated
by the SSC]) included 89 patients: 53 responders (60%) and 36 nonresponders
(40%). Response was defined as major (complete resolution of >_1 C-finding)
or partial (>50% improvement in >_1 C-finding or a >20% to <_50% improve-
ment in >_1 C-finding).Data collection of patient-reported outcomes
Patient-reported QOL and symptom burden were assessed by using the
12-Item Short-Form Health Survey (SF-12)18 and the Memorial Symptom
Assessment Scale (MSAS)19 questionnaires, respectively. Questionnaires
were administered before each visit to avoid biasing patients following theirdisease status update. Scores were collected at baseline, every 4 weeks until
the end of cycle 12, every 3 cycles thereafter, and at the end of treatment.
The SF-12 evaluated 2 overarching health summary measures indicative of
patient health-related QOL.18,20 Patients answered 12 health-related
questions using a 5-point scale to record their perceived level of functioning.18
Each SF-12 scale ranged from 0 to 100. On the basis of the responses to
individual symptoms, a physical composite score and a mental composite
score were derived. An increase relative to baseline in the SF-12 score
indicated improved QOL. The minimally important difference was 4 points
for the physical component score and 2 points for the mental component
score.20
In the MSAS questionnaire, patients rated the severity and distress of 32
symptoms and the frequency of 24 of the 32 symptoms.19 Patients rated
symptom severity and frequency on a 4-point Likert scale and symptom
distress on a 5-point scale. The MSAS included 4 subscales (total MSAS,
physical symptom score, psychological symptom score, and global distress
index).21 A decrease in MSAS scores over time indicated symptom
improvement.21,22 Minimal important differences were determined for the
total MSAS subscore (0.20-0.45), physical symptom score (0.31-0.42),
psychological symptom score (0.45-0.66), and global distress index
(0.36-0.59).21,22Data collection of MC mediator–related symptoms
MC mediator–related symptoms were assessed by the investigator at
baseline (month 0, the last nonmissing value before the first dose) and at each
visit (every 4 weeks until the end of cycle 12, every 3 cycles thereafter, and at
the end of treatment). Signs and symptoms included skin symptoms (skin
lesions of mastocytosis, pruritus/whealing, flushing), circulatory symptoms
(anaphylaxis/syncope), gastrointestinal symptoms (diarrhea, abdominal
cramping, nausea, vomiting), and other symptoms possibly related to
mastocytosis (musculoskeletal pain, neurologic symptoms, and
psychiatric/psychological symptoms).
Frequency of MC mediator–related symptoms was rated by using a
5-category scale (no symptoms; mild, infrequent; moderate; severe; and
very severe). Severity of symptoms was recorded by using a shift table (ie,
mild to very severe symptoms). Furthermore, photographs were taken of some
patients to illustrate changes in cutaneous lesions (the taking of photographs
was not protocol-defined).Statistical methods
Patient responses on the SF-12 and MSAS were summarized by using
descriptive summary statistics. SF-12 domain and summary scores20 and
MSAS subscale summary scores19 were calculated according to standard
scoring guidelines. Summary statistics included changes from baseline to
the end of each cycle in all SF-12 and MSAS scores and subscores. The
baseline and best postbaseline values for summary scores (the SF-12 physical
component score andmental component score and the totalMSAS score) were
compared with the minimally important difference for each metric, which
indicated the minimum score improvement shown to be clinically
meaningful.18,22 AWilcoxon signed rank test was used to calculate the P value
comparing baseline and best postbaseline scores. A Pearson correlation
coefficient was used to measure correlation between symptom improvement
(SF-12 and MSAS scores) and duration of response. The numbers of patients
with a 50% or greater improvement in SF-12 physical and mental
component scores and total MSAS score were also calculated for patients
who received up to 36 cycles of midostaurin therapy. The results are reported
for patients in the ITT population to ensure inclusion of the largest QOL data
set available. Analyses were repeated on the smaller PEP for confirmation;
similar trends were observed across the ITT population and PEP for all
measures.
For mediator symptoms, baseline was defined as the last nonmissing value
before the first dose. At baseline, percentages were based on the number of
patients evaluable at that time point for a given symptom. At other time points,
values were reported for patients with a symptom at baseline and 1 or more
evaluations during treatment, either overall or at specific time points.
Survey time point, cycle 0 1 2 3 4 5 6
Eligible patients, n 110 107 100 87 83 80 74
Full adherence, % 91 93 94 95 99 96 93
Partial adherence, % 9 7 6 5 1 4 7
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Survey time point, cycle 0 3 6 9 12 15 18 21 24 27 30 33 36
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FIG 1. Improvements in health-related QOL (according to SF-12 scores) in response to midostaurin. Median
changes in SF-12 scores from baseline over the first 6 cycles of treatment in patient-reported health-related
QOL measures (SF-12). A, Median changes in the combined physical health and mental health scores.
B, Median change over baseline in QOL with up to 36 cycles of midostaurin.
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TABLE I. QOL in the study population: numbers of patients with and without sustained improvement in SF-12 and MSAS scores



































Physical component score 36.5 (12.6-57.8) 9 (7.8) 31 (28-141) 0.126 .42 10 (8.6) 356 (281-1064) 0.596 <.001
Physical functioning 25.0 (0.0-100.0) 9 (7.8) 58 (29-141) 0.226 .20 11 (9.5) 476 (244-1485) 0.706 <.001
Role-limiting physical problems 25.0 (0.0-100.0) 15 (12.9) 57 (29-162) 0.329 .06 17 (14.7) 449 (169-1485) 0.603 <.001
Bodily pain 75.0 (0.0-100.0) 16 (13.8) 82.5 (28-142) 0.049 .78 12 (10.3) 487 (169-846) 0.534 <.001
General health 25.0 (0.0-100.0) 12 (10.3) 44.5 (24-162) 0.307 .10 15 (12.9) 392 (190-1512) 0.746 <.001
Mental component score 45.3 (21.6-68.1) 6 (5.2) 29 (29-143) 0.347 .03 5 (4.3) 252 (183-400) 0.523 <.001
Social functioning 50.0 (0.0-100.0) 14 (12.1) 57 (15-140) 0.200 .29 30 (25.9) 337 (168-1415) 0.592 <.001
Vitality 25.0 (0.0-100.0) 15 (12.9) 62 (29-140) 0.637 <.001 18 (15.5) 379 (172-1512) 0.694 <.001
Role-limiting mental problems 58.9 (0.0-100.0) 17 (14.7) 54 (22-148) 0.034 .85 16 (13.8) 494 (225-1070) 0.595 <.001
Mental health 62.5 (12.5-100.0) 13 (11.2) 57 (28-162) 0.286 .08 14 (12.1) 341 (168-1070) 0.695 <.001
Symptom burden (MSAS subscores)
Total symptom burden 1.0 (0.0-2.5) 21 (18.1) 85 (8-143) –0.179 .39 27 (23.3) 290 (169-1064) 0.666 <.001
Symptom distress 1.1 (0.0-2.8) 19 (16.4) 60 (8-143) –0.032 .87 31 (26.7) 358 (168-1373) 0.561 <.001
Physical symptoms 1.2 (0.0-2.9) 22 (19.0) 69.5 (8-148) 0.134 .53 23 (19.8) 267 (169-1380) 0.649 <.001
Psychological symptoms 1.0 (0.0-2.8) 18 (15.5) 72 (8-162) 0.179 .37 29 (25.0) 330 (168-1260) 0.614 <.001
DOR, Duration of response.
*Patients with a 50% or greater decrease in MSAS score relative to baseline or patients with a 50% or greater increase in SF-12 summary score relative to baseline sustained for
less than 168 days.
Patients with a 50% or more decrease in MSAS score relative to baseline or patients with a 50% or greater increase in SF-12 summary score relative to baseline sustained for at
least 168 days.
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Overall health status and QOL
Overall health status and QOL were assessed during treatment
with midostaurin by using the SF-12 score at baseline and during
treatment (Fig 1). All patients either fully or partially completed
the SF-12 form at every time point assessed; at least 50% of pa-
tients fully completed the form at each time point, and the
mean rate of full completion across time points was approxi-
mately 68% (see Fig E1 in the Online Repository at www.
jacionline.org). SF-12 scores, particularly the physical health
scores, rapidly improved over the first 6 cycles (Fig 1,A). The me-
dian best change from baseline was more than 4 points in both
physical and mental health subscores after only 1 cycle of treat-
ment. Improvements in physical health stabilized after 6 cycles,
whereas mental health showed some fluctuation after that time
point (Fig 1, B). Overall, however, sustained improvements
were noted (ie, a >_50% increase relative to baseline in SF-12
subscore for >_168 days) in both mental and physical health
scores with up to 36 cycles of midostaurin therapy (Fig 1, B
and Table I).
For those patients with sustained responses, Pearson correla-
tion coefficients (range, 0.592-0.746) and P values less than .001
with all SF-12 subscores indicated a high correlation with dura-
tion of response. However, for those patients whose responses
were not sustained (ie, a >_50% increase relative to baseline in
SF-12 subscore for <168 days), the majority of subscores showed
no correlation with duration of response (Pearson correlation co-
efficient range, 0.034-0.637;P >.05); the sole exceptions were the
overall mental component score (Pearson correlation coefficient,
0.347; P 5 .03) and vitality subscore (Pearson correlation
coefficient, 0.637; P < .001). The median duration of responsein patients with sustained improvements in SF-12 subscores
ranged from 252 days to 494 days, whereas the median duration
of response in patients without sustained improvements ranged
from 29 days to 82.5 days (Table I). Notably, similar trends
were observed if the analysis was restricted to the PEP, with re-
sponders showing a greater improvement than nonresponders
(data not shown).
Of note, the baseline SF-12 summary scores were worse than
those in published reports of patients with colorectal or lung
cancer at baseline23; however, after treatment with midostaurin,
the subscores increased significantly (P < .0001), with mental
component scores improving to reach scores similar to those re-
ported in healthy individuals (see Fig E2 in the Online Repository
at www.jacionline.org).Symptom burden
In addition to QOL, symptom burden during treatment was
assessed by using the MSAS questionnaire (Fig 2). All patients
completed the questionnaire either fully or partially at every
time point assessed; at least 75% of patients fully completed the
form at each time point, and the mean rate of full completion
across time points was approximately 94% (see Fig E1 in the On-
line Repository). Symptom burden substantially improved over
the first 6 months, with marked improvements in all MSAS scores
relative to baseline (Fig 2, A). Moreover, MSAS total and
summary scores also showed continual and sustained
improvement with up to 36 cycles of midostaurin therapy
(Fig 2, B and Table I). Similar to the SF-12 subscore observations,
theMSAS summary score improvements correlated with duration
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Survey time point, cycle 0 3 6 9 12 15 18 21 24 27 30 33 36
Eligible patients, n 107 85 74 63 59 43 35 32 21 18 17 16 11
Full adherence, % 59 58 70 68 64 65 69 78 52 61 71 56 64
Partial adherence, % 41 42 30 32 36 35 31 22 48 39 29 44 36
Full/partial adherence, % 100 100 100 100 100 100 100 100 100 100 100 100 100













FIG 2. Improvement in symptom burden (MSAS score) in response to midostaurin. Median changes from
baseline over the first 6 cycles during treatment in patient-reported symptom burden measures (using the
MSAS tool), including total MSAS, physical symptom burden, psychological symptom burden, and global
distress caused by physical and psychological symptom burden (A). Median change over baseline in
patient-reported symptom burden (MSAS) with up to 36 cycles of midostaurin (B).
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Skin lesions of mastocytosis (n = 57)
Pruritus/whealing (n = 56)
Flushing (n = 59)
Anaphylaxis/syncope (n = 56)
Nausea (n = 59)
Vomiting (n =59)
Diarrhea (n = 57)
Abdominal pain/cramping (n = 59)
Musculoskeletal pain (n = 57)
Pain (n = 57)
Neurologic symptoms (n = 55)
Psychiatric/psychological symptoms (n = 55)
Patients Evaluated at Baseline and 




0 25 50 75 100
Skin lesions of mastocytosis (n = 22)
Pruritis/whealing (n = 13)
Flushing (n = 15)
Anaphylaxis/syncope (n = 5)
Nausea (n =19)
Vomiting (n = 12)
Diarrhea (n = 22)
Abdominal pain/cramping (n = 21)
Musculoskeletal pain (n = 15)
Pain (n =  8)
Neurologic symptoms (n = 11)
Psychiatric/psychological symptoms (n = 9)
Improved No change Worsened
*
*
Patients With Symptom at Baseline and 
Evaluated ≥ 1 Time on Treatment, %†
FIG 3. Improvement in MC mediator–related symptoms in response to midostaurin. The frequency of
different mediator-related symptoms at baseline (gray) and during treatment (blue) per investigator assess-
ment in members of the study population who were evaluated at baseline and at any point while receiving
treatment (A). Summary of shift inmediator-related symptoms from baseline to best value during treatment
in all patients with the specific symptom evaluated at baseline and at least once during treatment (B).
*Anaphylaxis/syncope includes near-syncope and syncope associated with flushing and tachycardia.
Because of the small numbers of patients in some of the symptom groups, caution should be used
when interpreting the data.
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362 HARTMANN ET ALcorrelation coefficient range, 0.561-0.666; P < .001), but not for
thosewithout sustained responses (Pearson correlation coefficient
range, –0.179 to 0.179; P >.05). The median duration of response
in patients with sustained improvements in MSAS summary
scores ranged from 267 days to 358 days, whereas the median
duration of response in patients without sustained improvements
ranged from 60 days to 85 days (Table I). The trends in improve-
ment in symptom burden remained consistent if the analysis was
restricted to the PEP, with responders again showing a greater
improvement than nonresponders (data not shown).
As noted in the primary analysis of this study,16 the prevalence
of 30 of 32 symptoms decreased with midostaurin treatment(from baseline to best total MSAS score), except for nausea and
vomiting. Additionally, all MSAS subscores were worse than
those reported in patients with breast, colorectal, gynecologic,
lung, or prostate cancer24,25; with midostaurin treatment, all of
these subscores improved significantly (P < .0001) (see Fig E2
in the Online Repository).Mediator-related symptoms
Furthermore, physician-assessed MC mediator–related symp-
toms were analyzed during treatment with midostaurin (Fig 3).
Data were available for 47% to 51% of patients at baseline
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FIG 4. Improvements in the severity of MC mediator–related symptoms over 6 cycles of treatment with
midostaurin. The frequency of mediator-related symptoms is differentiated according to severity at 0, 3, and
6 cycles of treatment per investigator assessment for skin lesions of mastocytosis (A), pruritus/whealing (B),
flushing (C), anaphylaxis/syncope (D), nausea (E), vomiting (F), diarrhea (G), abdominal pain/cramping (H),
musculoskeletal pain (I), pain (J), neurologic symptoms (K) and psychiatric/psychological symptoms (L).
The leftmost column of each panel denotes the symptom severity at baseline (0 months). Columns to the
right denote symptom severity only in those patients reporting that symptom at baseline. Patients with
no symptoms are represented in white, those who reported mild symptoms are represented in light
gray, those who reported moderate symptoms are represented in medium gray, those who reported severe
symptoms are represented in dark gray symptoms, and those who reported very severe symptoms are rep-
resented in black. Because of the small numbers of patients in some symptom groups, caution should be
used when interpreting the data. *Patients assessed for symptom at baseline. Patients with symptoms pre-
sent at baseline.
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FIG 5. Improvement in cutaneous lesions in patients with positive response
to midostaurin treatment. Skin lesions at baseline (photographs on the left)
and after several weeks of treatment (photographs on the right) in a patient
with aggressive SM (A) and a patient with SM-AHN (B).
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to 73% of patients at least once during treatment. At baseline, 9%
to 39% of patients had every mediator-related symptom, ranging
from mild to severe.The rates of mediator-related symptoms dramatically
decreased during treatment (Fig 3, A). In patients with a baseline
assessment and at least 1 assessment during treatment, the most
common symptoms at baseline were skin lesions of mastocytosis
and diarrhea (22 of 57 patients [39%] for each); during treatment,
the frequency of both symptoms decreased to 10 of 57 patients
(18%). Most other symptoms showed a similar reduction
during treatment. The exception was psychiatric/psychological
symptoms, which were present in 9 of 55 patients (16%) at base-
line and 8 of 55 patients (15%) during treatment.
Improvements occurred in 67% to 100% of patients who had a
specific symptom at baseline and at least 1 postbaseline
assessment (Fig 3, B). In fact, at least 80% of patients showed im-
provements across all symptoms except psychiatric/
psychological symptoms, which improved in 67% of patients.
Most other patients experienced no change in each symptom
present at baseline (except nausea, which showed worsening in
a few patients, which is consistent with the known tolerability
profile of midostaurin). Most patients who did not have a specific
symptom at baseline did not develop that symptom while
receiving treatment. Most new symptoms were gastrointestinal:
nausea (mild and infrequent) in 5 of 40 patients (13%), vomiting
(mild and infrequent) in 4 of 47 patients (9%), vomiting
(moderate) in 1 of 47 patients (2%), and diarrhea (mild and
infrequent) in 2 of 35 patients (6%).
Fig 4 shows all symptom improvements in patients with base-
line symptoms who were evaluable at cycles 3 and 6. Per symp-
tom, a wide range of improvement was seen, varying from
improvement in 5% to 75% of patients after 3 cycles and
improvement in 22% to 100% of patients after 6 cycles (Fig 4).
The symptoms with the highest rate of complete resolution
were anaphylaxis/syncope (3 of 4 patients [75%] at 3 months
and 2 of 2 patients [100%] at 6 months), as well as neurologic
symptoms (6 of 9 patients [67%] at 3 months and 5 of 6 patients
[83%] at 6 months). Furthermore, in most patients who did not
show complete resolution of symptoms, we observed substantial
improvement in the severity of symptoms. Moreover, despite the
association of midostaurin treatment with the development of
gastrointestinal symptoms (ie, nausea and vomiting), the number
of patients with these symptoms reported at baseline decreased at
3 and 6 months. By 6 months, the number of reported patients
with nausea decreased from 19 to 10 and the number of those
with vomiting decreased from 12 to 9; the severity of these symp-
toms improved over this time as well, with most patients shifting
from moderate or severe to no or mild nausea and/or vomiting
(Fig 4). Similar improvements in symptom severity were
observed if the analysis was restricted to the PEP, regardless of
whether patients achieved a response (data not shown).
Inmany centers, improvements in skin lesions during treatment
withmidostaurin were also captured photographically, document-
ing substantial improvement in cutaneous lesions (Fig 5). Fig 5,A,
for example, depicts a patient with ASM and skin lesions on her
back and shoulders, which decreased significantly during treat-
ment. Fig 5, B shows a patient with SM-AHN (SM with chronic
eosinophilic leukemia) who experienced marked improvement
of truncal skin lesions. In this patient, improvement of skin
lesions was also accompanied by a decrease in BM MC burden,
reduction of serum tryptase levels, and normalization of
eosinophils and albumin, as well as weight gain of 25 kg (which
equaled the amount of disease-related weight loss before
initiation of midostaurin therapy).
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In the present study, we have reported on significant improve-
ments of QOL, MC mediator–related symptoms and skin lesions
in patients with advSM treated with the multikinase/KIT inhibitor
midostaurin. This report is the first to assess the improvement in
QOL and mediator symptoms in a large cohort of patients with
advSM through use of assessments by both physicians and the
patients themselves. In addition, thanks to careful collection of
these data, the baseline QOL assessments from this study may
also serve as a reference for future evaluations in patients with
advSM. Prior case reports and case series showed that treatment
with IFNa-2b or cladribine reduced skin lesions and other
symptoms; however, the effects of these drugs on other aspects
of QOL have not been fully evaluated.26,27
No standard or validated assessment tool currently exists for
measuring QOL in patients with advSM.28,29 In addition to the
SF-12 and MSAS, the cancer-specific tool of the European
Organisation for Research and Treatment of Cancer, the QOL
Questionnaire Core 30 has been used to assess symptoms in
patients with SM.28,30 The MSAS, however, is among the few
existing tools created to assess the severity, frequency, and impact
of a given symptom, although it is not specific to SM.19 Another
tool is the consensus scoring system with consensus response
criteria that was proposed in 2007.31 However, this objective,
symptom-based scoring system does not address QOL. Recently,
2 mastocytosis QOL questionnaires (MC-QoL and MQLQ) were
developed for nonadvanced categories of mastocytosis.12,32 The
MC-QoL evaluates the impact of 4 domains (symptoms,
emotions, social/life functioning, and skin) on health-related
QOL.32 The MQLQ includes 8 SM-specific QOL domains:
fatigue and mental health, anaphylaxis, skin symptoms, bone
symptoms, unfamiliarity (ie, the burden related to ignorance of
caretakers and the social environment concerning mastocytosis),
flushing, general symptoms, and triggers.12 Although the
MC-QoL and MQLQ scores have been tested, they have not
been validated in advSM. In the future, it will thus be important
to validate a patient-reported outcome instrument for evaluating
symptoms and QOL in advSM. Moreover, to fully understand
the critical mechanism of midostaurin-mediated improvements
in QOL and MC mediator-related symptoms, allergic and
immunologic biomarkers would be helpful. Unfortunately, such
markers have not yet been definitively identified and—awaiting
further validation—were not collected before and during the
current study.
Patients with advSM present with an array of symptoms that
can dramatically affect their QOL; thus, improvements in these
symptoms are of significant clinical value. In acknowledgment of
this issue, novel response criteria incorporating symptom
improvement as part of a comprehensive assessment of response
have been proposed by several groups, including the European
Competence Network on Mastocytosis, International Working
Group on Myeloproliferative Neoplasms Research and Treat-
ment,33 and Mayo Clinic.34 To date, however, large clinical
studies using these criteria in patients with advSM have not
been performed. Also, evaluation of the health-related QOL in
patients with advSM faces many challenges, including the large
heterogeneity of patient populations.29 Interestingly, in our study,
even patients who did not achieve a reduction in measures of MC
burden showed an improvement in a variety of symptoms
following treatment with midostaurin. This improvement maybe related to the ability of midostaurin to inhibit the release of
IgE-dependent histamine fromMCs.15,35 In this regard, it is worth
noting that midostaurin treatment in patients with SM has also
been observed to result in a markedly reduced IgE-mediated
histamine release in blood basophils obtained ex vivo.35
Somemediator-related symptomsmight be difficult to interpret
given the overlap with adverse events associated with midos-
taurin, which include nausea, vomiting, and diarrhea. Although
the overall frequency of nausea and vomiting increased during
treatment, some patients with these symptoms at baseline
experienced improvement while receiving midostaurin. The
patient-reported SF-12 and MSAS questionnaires demonstrated
significant improvements in mental health during the study. In
contrast, per the physician-reported questionnaire, fewer
improvements with midostaurin treatment were observed in
psychiatric and/or psychological symptoms than in other symp-
toms. One interpretation of the lack of concordance could be that
these symptoms might not have been directly related to the
underlying mastocytosis or may have been overestimated in prior
studies of mastocytosis. Another factor to consider is that patients
and physicians may have reported these symptoms differently.
One limitation of the present study is that these QOL analyses
do not account for patient withdrawals that led to the accumu-
lation of missing data over time. Although this is compensated for
in part by higher compliance rates during the first 6 cycles—when
most patients continued to receive treatment and when symptoms
could be expected to be most severe—the impact of missing data
on later cycles, which represent a select population of patients
who continued to receive treatment long-term, is less clear. An
additional limitation is the study’s sample size, which led to only
a small fraction of patients who appeared resistant to midostaurin
(ie, showed no change with treatment) for each symptom
evaluated. As this fraction did not necessarily include the same
patients from symptom to symptom, identification of a population
that exhibited consistent resistance to midostaurin across all
symptom domains was not possible. The size of this study also
precluded assessment of the impact of features such as the
following on response to midostaurin: patient age, sex, and
performance status; degree of organ damage; and SM subtype.
Further characterization of an apparent midostaurin-resistant
population and identification of the features of such a population
would be of clinical interest and await larger-scale studies
powered for these types of analyses.
Our data demonstrated a considerable improvement in skin
lesions of mastocytosis with midostaurin treatment based on
both physician-assessed questionnaires and photographic
documentation. These improvements were clearly evident during
treatment (20 of 22 patients [91%] experienced symptom
improvement from baseline), but skin lesions of mastocytosis
did take more time to demonstrate clear responses than did other
symptoms. In the recently performed study of midostaurin in
patients with indolent SM, an identical level of improvement was
seen.36
Our data, in combination with the previously reported efficacy
and safety data reported for the D2201 and A2213 studies,16,37
demonstrated that midostaurin had significant QOL benefits and
was an effective treatment option for patients with advSM, with
a manageable safety profile. These data provide a rationale to
explore midostaurin in nonadvanced forms of mastocytosis, in
which mediator symptoms are the main manifestation.
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Key messages
d Midostaurin has been previously reported to normalize
organ function in patients with advSM by reducing MC
burden in bone marrow and other organs; the current
analysis demonstrates that midostaurin also improves
QOL and MC mediator–related symptoms in these
patients.
d These results may also provide a rationale to explore mid-
ostaurin in nonadvanced forms of mastocytosis, in which
mediator symptoms are the primary manifestation.REFERENCES
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FIG E1. Completion rate over time for the SF-12 and MSAS surveys in the study population.
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FIG E2. QOL (SF-12) and symptom burden (MSAS) in this study’s
population versus published scores for patients with cancer (MSAS and
SF-12 [gray dashed lines]) and healthy individuals (SF-12 only [solid black
lines]).E2-E5
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TABLE E1. Baseline characteristics of the study population
Characteristics Study population (N 5 116)
Median age, y (range) 63 (25-82)
Male, n (%) 76 (66)
ECOG PS, n (%)
0-1 77 (66)
2-3 39 (34)















Increased total bilirubin level 25 (22)
Weight loss 12 (10)
Increased ALT level 6 (5)
Increased AST level 2 (2)




The data presented in this table were originally published in Gotlib et al.E1
AHN, Associated hematologic neoplasm; ALT, alanine aminotransferase;
ASM, aggressive systemic mastocytosis; AST, aspartate aminotransferase; C, clinical;
ECOG PS, Eastern Cooperative Oncology Group performance status; MCL, mast cell
leukemia; ND, not determined.
*Data on non-MCL SM subtype were available only for patients within the primary
efficacy population. Among those 89 patients, 16 (14% of the overall study
population) had ASM and 57 (49% of the overall study population) had SM-AHN; the
SM subtype for the remaining 22 patients (19%) with non-MCL SM in the overall
study population was not determined.
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